Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for genetically defined diseases. Agios is advancing a robust pipeline of investigational medicines, including a first-in-class pyruvate kinase R (PKR) activator that is being evaluated in pyruvate kinase deficiency, alpha- and beta-thalassemia and sickle cell disease.